Artificial intelligence (AI) is revolutionizing the pharmaceutical industry, driving innovations in drug discovery, clinical trials and patient care. For investors, this presents a unique opportunity to capitalize on the growth of AI-driven pharmaceutical companies.
What are pharmaceutical AI stocks?
Pharmaceutical AI stocks are shares of companies that integrate AI technologies into their drug discovery and development processes. These companies utilize machine learning algorithms, data analytics, and other AI tools to identify potential drug candidates, optimize clinical trials, and predict patient responses.
Here are the top 10 pharmaceutical AI stocks across the TSX, TSX Venture, CSE, NYSE and Nasdaq:
10: HealWell AI (TSX:AIDX) specializes in early disease detection and clinical decision support systems. With high-profile clients including six of the top 10 largest pharma companies, HealWell AI is poised for significant growth.
HealWell AI stock (TSX:AIDX) has traded between C$1.10 to C$2.19 over the past three months and is up 60 per cent since the beginning of the year.
9: Procept BioRobotics (NDAQ:PRCT) focuses on AI-enabled surgical robotics for urology. Its AquaBeam system, designed for minimally invasive surgery, has shown promising results in clinical studies.
Over the past three months, Procept BioRobotics stock (NDAQ:PRCT) has traded between US$56.31 to US$99.20 and is up 136.17 per cent since the year began,
8: Innodata (NDAQ:INOD) provides AI-enabled software platforms for data collection and annotation. The company has seen substantial growth in gross profitability, making it a strong contender in the AI pharmaceutical space.
Since the beginning of the year, Innodata stock (NDAQ:INOD) has climbed 167.62 per cent and has traded between US$13.74 to US$21.73.
7: Cipher Pharmaceuticals (TSX:CPH) offers a diverse portfolio of treatments, including dermatology and acute hospital care products. The company has shown consistent revenue growth and is expanding its product offerings.
Cipher Pharmaceuticals stock (TSX:CPH) has traded between C$11.54 to C$18.99 over the past three months while rising 180.87 per cent year-to-date.
6: NurExone Biologic (TSXV:NRX) is developing ExoTherapy, a drug delivery platform using exosomes for treating central nervous system disorders. The company has received orphan drug designation from the FDA for its innovative treatments.
NurExone Biologic stock (TSXV:NRX) has traded between $0.53 to $0.69 over the past three months and is up 113.56 per cent since the year began.
5: Telescope Innovations (CSE:TELI) combines robotic automation, online analysis, and machine learning to develop scalable manufacturing processes for the pharmaceutical industry. The company has partnered with Pfizer (NYSE:PFE) to accelerate drug development.
Telescope Innovations stock (CSE:TELI) has traded between $0.40 to $0.53 over the past three months and has climbed 75 per cent since the beginning of the year.
4: Super Micro Computer (NDAQ:SMCI) provides IT solutions across various sectors, including AI and healthcare. The company’s diversified tech offerings and strong revenue growth make it a key player in the AI pharmaceutical market.
Super Micro Computer stock (NDAQ:SMCI) has traded between US$35.57 to US$70.17 over the past three months and has grown 24.43 per cent since the start of 2024.
3: Celestica (TSX:CLS) offers infrastructure services to meet the growing demand for computing power in AI and machine learning. The company’s expertise in health technology and industrial equipment positions it well for future growth.
Since July, Celestica stock (TSX:CLS) has traded between US$41.03 to US$70.32 and is up 139.69 per cent since the year started.
2: OneSoft Solutions (TSXV:OSS) uses AI and predictive analytics to update legacy software applications. Its flagship subsidiary, OneBridge Solutions, helps pipeline operators predict failures and reduce operational costs.
OneSoft Solutions stock (TSXV:OSS) traded between $0.58 to $0.88 in the past three months and has added 16 per cent year-to-date.
1: Eli Lilly and Co. (NYSE:LLY) discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound.
Over the past three months, Eli Lilly stock (NYSE:LLY) has traded between US$772.14 to US$960.02 and is up 41.65 per cent since the beginning of the year.
Honourable mention: Novo Nordisk (NYSE:NVO), a global healthcare company engaged in diabetes care and in the discovery, development, manufacturing and marketing of pharmaceutical products. The company operates through two business segments: diabetes and obesity care and biopharmaceuticals.
In the past three months, Novo Nordisk stock (NYSE:NVO) has traded between US$109.64 to US$139.16 and has risen 6.87 per cent since January.
These companies represent some of the most promising investments in the pharmaceutical AI sector.
How to invest in pharmaceutical AI stocks
- Research and identify potential stocks: Start by researching companies that are at the forefront of AI in pharmaceuticals. Look for those with strong pipelines, strategic partnerships and a track record of innovation.
- Evaluate financial health: Assess the financial stability of these companies. Key indicators include revenue growth, profitability and cash flow. Companies with solid financials are better positioned to weather market volatility.
- Understand the technology: Gain a basic understanding of how these companies use AI in their operations. This knowledge will help you make informed investment decisions and understand the potential impact of their innovations.
- Diversify your portfolio: As with any investment, diversification is crucial. Consider spreading your investments across multiple pharmaceutical AI stocks to mitigate risk.
- Stay informed: Keep up with industry news, regulatory changes, and advancements in AI technology. Staying informed will help you anticipate market trends and make timely investment decisions.
Why pharmaceutical AI stocks can be a good investment
- Innovative potential: AI has the potential to transform the pharmaceutical industry by reducing the time and cost of drug development. This innovation can lead to significant breakthroughs and high returns on investment.
- Growing market: The global AI in healthcare market is expected to grow substantially in the coming years, driven by increasing adoption of AI technologies and rising healthcare needs.
- Strategic partnerships: Many pharmaceutical AI companies form strategic partnerships with tech giants and research institutions, enhancing their capabilities and market reach.
- Addressing unmet needs: AI-driven drug discovery can address unmet medical needs by identifying new treatments for diseases that currently lack effective therapies.
In conclusion
Pharmaceutical AI stocks represent companies that leverage AI to revolutionize the drug discovery and development process. These companies use AI to analyze vast datasets, predict drug efficacy, and streamline clinical trials, ultimately aiming to bring new treatments to market faster and more efficiently. Investing in these stocks can be a promising opportunity because of the potential for significant advancements in healthcare and substantial financial returns.
By carefully researching and selecting companies with strong AI capabilities and financial health, investors can potentially reap significant rewards while contributing to advancements in medical science. As always, it’s important to stay informed and diversify your investments to manage risk effectively.
Join the discussion: Find out what everybody’s saying about this stock on the healthcare Bullboards, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image generated with AI)